Subcutaneous immunoglobulin for treatment of patients with primary immunodeficiencies: review of the literature and personal experience

Abstract

Substitution with normal human immunoglobulin is a golden standard of primary immunodeficiencies therapy. Subcutaneous immunoglobulins, especially delivered via «rpid push» method are gaining popularity among patients and treating physician since at home infusions allow to reduce treatment costs and increase patients’ quality of life. Here we report first Russian experience of subcutaneous infusion of Gamunex®-C immunoglobulin, in four patients with primary immunodeficiencies, performed by their parents via «rapid push» method at home. No systemic reactions have been reported, Gamunex®-C treatment prevented severe infections and allowed adequate average serum IgG levels (10,1 g/l while on subcutaneous infusions in comparison with 8,5 g/l while on intravenous immunoglobulin).